Andy is a biochemist and pharmacologist with over 40 years of experience in drug discovery and development. At Scios, he initiated the development program for Natrecor, which was approved for the treatment of acute decompensated heart failure. At Medivation, he led preclinical research on XTANDI (enzalutamide) for prostate cancer and TALZENNA (talazoparib) for prostate and breast cancers. Most recently at Auransa, an early AI-driven biotechnology company, Andy led a team that discovered and advanced AU-409, a novel orally active therapeutic for liver cancer that is currently in clinical trials.

Across leadership roles at Auransa, Medivation, Scios, and CalBio, Andy has contributed to three marketed products and numerous clinical candidates spanning oncology, cardiovascular disease, pain, and inflammation. He is an author on 90 scientific publications and an inventor on 35 patents.

Son is a medicinal chemist with over 20 years of experience, having started his professional career at Celera Genomics in 2005. From 2006-2016, Son was employed at Genelabs, Verseon and Medivation in roles with increasing responsibilities. From 2016-2022, he was Head of Chemistry at SPARCBIO. Son co-founded 1cBio in 2022, together with Jit Chakravarty and Sunny Chen. Since 2016, he has advised and supported several seed-stage companies regarding the design and synthesis of new chemical matter for their preclinical programs. In many cases, Son and his team were directly involved with the invention and discovery of the lead series and molecule. Son received his Ph.D. in Chemistry from the University of Illinois, Urbana-Champaign.

Prashant has over 30 years of experience in all areas of finance including venture funding, FP&A, accounting, financial analysis, valuation modeling, M&A/corporate development, strategy, audit and treasury. He has a thorough understanding of finance and accounting principles through MBA in Finance from Southern Methodist University, Dallas, TX and Chartered Accountancy certification (CPA foreign equivalent). At Liberty he worked initially as Vice President & General Manager of Strategy & Business Development and then Deputy Group Head of M&A. At Aviva, Prashant was Head of Strategic Investments and was also supporting the Corporate Venture Fund. Prashant served as corporate finance and accounting consultant for SPARCBIO for 2 years and has been with 1cBio since its inception in February 2022.